Your browser doesn't support javascript.
loading
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Kwiatkowski, David J; Choueiri, Toni K; Fay, André P; Rini, Brian I; Thorner, Aaron R; de Velasco, Guillermo; Tyburczy, Magdalena E; Hamieh, Lana; Albiges, Laurence; Agarwal, Neeraj; Ho, Thai H; Song, Jiaxi; Pignon, Jean-Christophe; Barrios, Pablo M; Michaelson, M Dror; Van Allen, Eliezer; Krajewski, Katherine M; Porta, Camillo; Pal, Sumanta; Bellmunt, Joaquim; McDermott, David F; Heng, Daniel Y C; Gray, Kathryn P; Signoretti, Sabina.
Affiliation
  • Kwiatkowski DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
  • Choueiri TK; Department of Medicine, Brigham and Women's Hospital, Boston, MA, US.
  • Fay AP; Harvard Medical School, Boston, MA, US.
  • Rini BI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
  • Thorner AR; Department of Medicine, Brigham and Women's Hospital, Boston, MA, US.
  • de Velasco G; Harvard Medical School, Boston, MA, US.
  • Tyburczy ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
  • Hamieh L; PUCRS School of Medicine, Porto Alegre, Brazil.
  • Albiges L; Department of Medical Oncology, Cleveland Clinic, Cleveland, US.
  • Agarwal N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
  • Ho TH; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, US.
  • Song J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
  • Pignon JC; Department of Medicine, Brigham and Women's Hospital, Boston, MA, US.
  • Barrios PM; Department of Medicine, Brigham and Women's Hospital, Boston, MA, US.
  • Michaelson MD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
  • Van Allen E; Institut Gustave Roussy, Villejuif, France.
  • Krajewski KM; Department of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Porta C; Department of Medical Oncology, Mayo Clinic, Arizona, Scottsdale, AZ, US.
  • Pal S; Department of Pathology, Brigham and Women's Hospital, Boston, MA, US.
  • Bellmunt J; Harvard Medical School, Boston, MA, US.
  • McDermott DF; Department of Pathology, Brigham and Women's Hospital, Boston, MA, US.
  • Heng DYC; PUCRS School of Medicine, Porto Alegre, Brazil.
  • Gray KP; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.
  • Signoretti S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Clin Cancer Res ; 22(10): 2445-2452, 2016 05 15.
Article in En | MEDLINE | ID: mdl-26831717
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Tumor Suppressor Proteins / Protein Kinase Inhibitors / TOR Serine-Threonine Kinases / Kidney Neoplasms / Mutation Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2016 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Tumor Suppressor Proteins / Protein Kinase Inhibitors / TOR Serine-Threonine Kinases / Kidney Neoplasms / Mutation Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2016 Type: Article Affiliation country: United States